Nevro Corp. (NYSE:NVRO) Director Michael F. Demane sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $89.50, for a total transaction of $447,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael F. Demane also recently made the following trade(s):

  • On Monday, September 11th, Michael F. Demane sold 25,000 shares of Nevro Corp. stock. The shares were sold at an average price of $87.73, for a total transaction of $2,193,250.00.

Nevro Corp. (NVRO) traded down 2.46% on Thursday, reaching $88.84. 397,103 shares of the company’s stock were exchanged. Nevro Corp. has a 12 month low of $65.82 and a 12 month high of $106.93. The firm has a 50-day moving average of $85.34 and a 200-day moving average of $84.31. The firm’s market capitalization is $2.62 billion.

Nevro Corp. (NYSE:NVRO) last announced its earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). The firm had revenue of $78.02 million for the quarter, compared to analyst estimates of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.31) EPS. On average, equities analysts expect that Nevro Corp. will post ($1.16) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Nevro Corp. (NVRO) Director Sells 5,000 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/insider-selling-nevro-corp-nvro-director-sells-5000-shares-of-stock.html.

Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its position in shares of Nevro Corp. by 17.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 358 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Nevro Corp. by 118.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,943 shares of the medical equipment provider’s stock worth $182,000 after acquiring an additional 1,055 shares during the last quarter. PNC Financial Services Group Inc. bought a new stake in Nevro Corp. during the 2nd quarter worth about $190,000. US Bancorp DE grew its holdings in Nevro Corp. by 412.4% during the 2nd quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock worth $194,000 after acquiring an additional 2,099 shares during the last quarter. Finally, Inspirion Wealth Advisors LLC bought a new stake in Nevro Corp. during the 2nd quarter worth about $205,000.

A number of brokerages recently weighed in on NVRO. BMO Capital Markets reaffirmed a “buy” rating and set a $106.00 price objective on shares of Nevro Corp. in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of Nevro Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Northland Securities reaffirmed a “buy” rating and set a $96.00 price objective on shares of Nevro Corp. in a research report on Tuesday, August 8th. Morgan Stanley boosted their price objective on shares of Nevro Corp. from $87.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, August 8th. Finally, BidaskClub downgraded shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $101.25.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.